RESPONSE AND AMENDMENT - REMARKS

Amendment to the Claims:

Applicants request entry of the amendments to claim 1. A marked-up copy of the claim as amended is attached as a separate sheet.

Rejection based upon 35 USC §112:

The Examiner rejected claim 1 under 35 USC §112, remarking that the phrase "the additional mixture" in claim 1 had no antecedent basis. The Applicants have adopted the suggested amendment to claim one to change the phrase to "an additional mixture." Applicants respectfully request withdrawal of the rejection.

Rejections based upon 35 USC §102(b):

The Examiner rejected claims 1, 2 and 4-9 under 35 USC §102(b), alleging that these claims are anticipated by Mozayeni (US 5,434,079). In particular, the Examiner states that cell-free systems wherein the components of the feeding solution and other parameters (e.g., upper and lower limits of parameters such as temperature, concentration and flow rate) may be changed during the synthesis of polypeptides is taught by Mozayeni. Applicants respectfully disagree that Mozanyeni anticipates the claims as currently amended.

The passages of the Mozayeni reference mainly cited by the Examiner in this regard (col. 7, 11. 2-35) are directed to the replacement of specific ingredients lost during operation of the process (1. 18/19), the injection of a readily measured ingredient (e.g., a radiolebelled amino acid, an mRNA or an elongation factor) for pulse-chase studies (1. 21-23) or to the control of parameters (e.g., feed solution composition) in order to optimize the process (1. 27-29). However, nothing is mentioned by Mozayeni regarding performing the synthetic process by changing the concentrations of the selected components (e.g., Mg²¹, K¹ or NTP) as defined in claim 1. This means that Mozayeni does not teach changing the concentration of the respective components during the process. The present invention is patentably distinct from the prior art synthesis processes (e.g. Mozayeni) because the prior art processes maintain the same predetermined concentrations of such components, both in the reaction mixture and in the feeding solution. As stated in the specification at page 4, lines 27-34, such prior art processes require optimization work which is both expensive and time-consuming.

Claim I has been amended to more clearly define the invention such that there is no confusion regarding this point. The method of claim I is neither directly nor implicitly taught by the Mozayeni reference, and is therefore not anticipated. Applicants

respectfully request withdrawal of the rejections based on alleged anticipation by the Mozayeni reference.

Rejection based upon 35 USC §103:

The Examiner also rejected claim 3 under 35 USC §103 as obvious over Mozayeni in view of Wimmer (US 5,674,729). The Examiner states that Wimmer teaches a process for the synthesis of viral proteins in a cell-free medium using NTP and Mg², and combines this with the teachings of Mozayeni to argue for obviousness.

As stated above, Mozayeni fails to teach the process of changing the concentrations of the components during the process. Wimmer does not cure this failure. Wimmer simply teaches adjusting the total Mg2+ concentration in relation to the added NTPs for an optimal production of virus protein (col. 10, ll. 57-59). Thus, this adjustment in Mg2+ concentration is related to the starting concentration of the components, and has nothing to do with the instant invention. In the present invention, at least one of the selected components is continually changed within the upper and lower limit of the respective determined range during the synthetic process.

Simply put, Mozayeni fails to teach the invention, and combining Wimmer with Mozayeni fails to fill in the gaps in this teaching. For this reason, the instant invention is nonobvious and patentable over the cited references. Applicants respectfully request withdrawal of the rejection based upon §103.

Conclusion:

For the reasons cited above, Applicants believe the claims as currently amended are patentable, and request withdrawal of all rejections and allowance.

Respectfully submitted,

Date: 9/14/03

Kenneth J. Waite, Reg. No. 45,189
Roche Diagnostics Corporation

9115 Hague Road, Bldg D

P.O. Box 50457

Indianapolis, IN 46250-0457

Tel.: 317-521-3104 Fax: 317-521-2883